FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026?

The comparison between the Fidelity MSCI Health Care Index ETF (FHLC) and the iShares U.S. Healthcare ETF (IYH) reflects deeper shifts in how investors are approaching healthcare exposure amid an aging global population, regulatory uncertainty, and the accelerating adoption of medical innovation. While both funds track broad U.S. healthcare indices, their distinct fee structures and dividend profiles hint at competing philosophies: one prioritizing cost efficiency, the other potentially offering stability through higher payouts. FHLC’s lower expense ratio—often a decisive factor in long-term returns—aligns with the growing investor preference for passive, low-cost indexing strategies. Meanwhile, IYH’s higher dividend yield may appeal to income-focused investors, suggesting a nuanced divergence in how the healthcare sector is being monetized in portfolios. This debate also underscores the evolving role of healthcare in broader market dynamics. For decades, healthcare ETFs were viewed as defensive plays, insulated from cyclical downturns by inelastic demand. Today, that perception is being tested. The sector now faces a trifecta of pressures: rising scrutiny over drug pricing, the potential for Medicare price negotiations under federal reforms, and the unpredictable trajectory of biotech innovation. Investors must weigh whether these risks are already priced in or whether they represent future headwinds. Looking ahead, the performance divergence between FHLC and IYH could serve as a bellwether for how the market values efficiency versus yield in a higher-for-longer interest rate environment. If inflation cools and the Federal Reserve cuts rates, dividend-heavy ETFs like IYH may regain favor. Conversely, if cost pressures persist and regulatory headwinds intensify, the lower-cost FHLC could outperform, reinforcing the dominance of passive vehicles in an era where alpha is increasingly hard to come by. Ultimately, this choice is less about which ETF is "better" in isolation and more about aligning with one’s risk tolerance and outlook for the sector’s structural challenges. The question going forward is whether healthcare’s traditional resilience can withstand the mounting pressures—or if the next decade will redefine its role in investor portfolios.